Literature DB >> 9505913

Randomised trial of elective stenting after successful percutaneous transluminal coronary angioplasty of occluded coronary arteries.

J Hancock1, M R Thomas, S Holmberg, R J Wainwright, D E Jewitt.   

Abstract

BACKGROUND: The value of angioplasty in occluded coronary arteries is limited by a restenosis/reocclusion rate of 50-70%. In patients with subtotal occlusion, stent implantation has been shown to reduce clinical and angiographic restenosis. Retrospective observational studies have suggested that stenting could reduce restenosis in total occlusions. The value of sustained coronary patency on global and regional left ventricular function in this clinical setting has not been defined clearly.
OBJECTIVES: To assess the medium term effect of elective intracoronary stent deployment after successful percutaneous transluminal coronary angioplasty (PTCA) of an occluded coronary artery.
METHODS: Sixty patients with a total coronary occlusion successfully treated by PTCA were randomised to receive an intracoronary stent or no stent. Patients underwent clinical and angiographic follow up at six months.
RESULTS: Thirty patients received a stent (group A) and 30 were treated by angioplasty alone (group B), all with initial success. One patient in group B required repeat angioplasty with stenting at 24 hours and one patient died after 10 days. Angiographic follow up was available for 57 patients. This showed a significantly reduced reocclusion rate in group A compared with group B (7% v 29%, p < 0.01) and a tendency to a reduced restenosis rate (22% v 40%, p = 0.105) in patients with no reocclusion. Left ventricular function, both global and regional, improved in group A. Only the regional left ventricular function in the area supplied by the target coronary artery improved in group B. Recurrence of symptoms and clinical events such as repeat angioplasty, coronary artery bypass grafting, death or myocardial infarction tended to be reduced in group A (4 (13%) v 9 (30%)).
CONCLUSIONS: Intracoronary stent insertion is effective in reducing the rate of reocclusion and shows a trend towards reduced restenosis after opening of a total coronary occlusion by balloon angioplasty. Sustained patency of the target coronary artery is associated with improvement in global and regional left ventricular function.

Entities:  

Mesh:

Year:  1998        PMID: 9505913      PMCID: PMC1728574          DOI: 10.1136/hrt.79.1.18

Source DB:  PubMed          Journal:  Heart        ISSN: 1355-6037            Impact factor:   5.994


  16 in total

1.  Coronary angioplasty of chronic occlusions: factors predictive of procedural success.

Authors:  L Maiello; A Colombo; R Gianrossi; M R Mutinelli; R Bouzon; J Thomas; L Finci
Journal:  Am Heart J       Date:  1992-09       Impact factor: 4.749

2.  Effect on global and regional left ventricular functions by percutaneous transluminal coronary angioplasty in the chronic stage after myocardial infarction.

Authors:  T Linderer; B Guhl; C Spielberg; W Wunderlich; L Schnitzer; R Schröder
Journal:  Am J Cardiol       Date:  1992-04-15       Impact factor: 2.778

3.  Results of coronary angioplasty of chronic total occlusions (the National Heart, Lung, and Blood Institute 1985-1986 Percutaneous Transluminal Angioplasty Registry).

Authors:  N A Ruocco; M E Ring; R Holubkov; A K Jacobs; K M Detre; D P Faxon
Journal:  Am J Cardiol       Date:  1992-01-01       Impact factor: 2.778

4.  Generalized model of restenosis after conventional balloon angioplasty, stenting and directional atherectomy.

Authors:  R E Kuntz; C M Gibson; M Nobuyoshi; D S Baim
Journal:  J Am Coll Cardiol       Date:  1993-01       Impact factor: 24.094

5.  Effects of severity of the residual stenosis of the infarct-related coronary artery on left ventricular dilation and function after acute myocardial infarction.

Authors:  W H Leung; C P Lau
Journal:  J Am Coll Cardiol       Date:  1992-08       Impact factor: 24.094

6.  Stenting in Chronic Coronary Occlusion (SICCO): a randomized, controlled trial of adding stent implantation after successful angioplasty.

Authors:  P A Sirnes; S Golf; Y Myreng; P Mølstad; H Emanuelsson; P Albertsson; M Brekke; A Mangschau; K Endresen; J Kjekshus
Journal:  J Am Coll Cardiol       Date:  1996-11-15       Impact factor: 24.094

7.  Effects of late percutaneous transluminal coronary angioplasty of an occluded infarct-related coronary artery on left ventricular function in patients with a recent (< 6 weeks) Q-wave acute myocardial infarction (Total Occlusion Post-Myocardial Infarction Intervention Study [TOMIIS]--a pilot study).

Authors:  V Dzavik; D S Beanlands; R F Davies; D Leddy; J F Marquis; K K Teo; T D Ruddy; J R Burton; D P Humen
Journal:  Am J Cardiol       Date:  1994-05-01       Impact factor: 2.778

8.  Survival of medically treated patients in the coronary artery surgery study (CASS) registry.

Authors:  M B Mock; I Ringqvist; L D Fisher; K B Davis; B R Chaitman; N T Kouchoukos; G C Kaiser; E Alderman; T J Ryan; R O Russell; S Mullin; D Fray; T Killip
Journal:  Circulation       Date:  1982-09       Impact factor: 29.690

9.  Initial and long-term outcome of 354 patients after coronary balloon angioplasty of total coronary artery occlusions.

Authors:  M R Bell; P B Berger; J F Bresnahan; G S Reeder; K R Bailey; D R Holmes
Journal:  Circulation       Date:  1992-03       Impact factor: 29.690

10.  Six- and twelve-month follow-up of the phase I Thrombolysis in Myocardial Infarction (TIMI) trial.

Authors:  J E Dalen; J M Gore; E Braunwald; J Borer; R J Goldberg; E R Passamani; S Forman; G Knatterud
Journal:  Am J Cardiol       Date:  1988-08-01       Impact factor: 2.778

View more
  2 in total

1.  Are "treatment" bare metal stents superior to "control" bare metal stents? A meta-analytic approach.

Authors:  David M Kent; Thomas A Trikalinos
Journal:  Am Heart J       Date:  2008-01-18       Impact factor: 4.749

2.  Application of rotational atherectomy in the drug-eluting stent era.

Authors:  Chun-Chi Chen; I-Chang Hsieh
Journal:  J Geriatr Cardiol       Date:  2013-09       Impact factor: 3.327

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.